OncoRedox can detect early-stage colorectal cancer through a simple blood test
It is the third most common cancer worldwide
OncoRedox has developed an innovative platform for the early detection of colorectal cancer using a simple blood sample. The system is based on an AI-powered disposable electrochemical sensor that generates a metabolic fingerprint of the reduction-oxidation (redox) state, enabling highly accurate disease detection through plasma samples.
"Our method demonstrated 94% accuracy in proof-of-concept studies and provides a significant advantage over traditional tests, offering higher compliance rates compared to stool tests, which are the current gold standard. Stool tests, however, are expensive, inconvenient and patients tend to forego them. Our method is highly cost-effective, with a per-test cost of goods at less than $10, compared to hundreds of dollars for DNA-based tests. Moreover, our method is more accurate than similar platforms on the market," says Prof. Hadar Ben-Yoav, co-founder and CTO.
Prof. Ben-Yoav is a member of the Department of Biomedical Engineering at Ben-Gurion University of the Negev and head of the Nanobioelectronics Laboratory.
Colorectal cancer is the third most common cancer worldwide, and its mortality rates are linked to the stage at which it is diagnosed. Early detection significantly improves survival rates, but traditional screening methods, such as colonoscopy, are costly, invasive and have low compliance rates.
"Blood tests for colorectal cancer detection signal a major shift towards cost-effective, non-invasive, and widely accessible alternatives," says OncoRedox CEO Gal Meister.
Prof. Gal Markel, Davidoff Cancer Center, Rabin Medical Center, also co-founded the company and serves as the CMO.
Approximately 120 million people annually in the United States, aged 45-75, are at risk of developing colorectal cancer, and around 136 million people annually in Europe.
The company is preparing to expand its clinical proof-of-concept studies and is seeking to raise $1 million to support this effort.
OncoRedox has received funding from the Israeli Innovation Authority and the Peregrine Venture/Incentive Incubator since its founding in January 2023.
The company has also conducted proof-of-concept studies for detection of other cancers, such as lung and bladder, as well as at home monitoring of chronic diseases such as Inflammatory Bowel Disease through blood and urine samples.
